SII and Oxford University’s malaria vax launched in Côte d’Ivoire
16 Jul 2024
Drug ApprovalVaccineBreakthrough TherapyClinical Study
Preview
Source: Pharmaceutical Technology
SII has already produced 25 million doses and aims to further increase production to 100 million doses per year. Credit: Diana Polekhina on Unsplash.
The R21/Matrix-M malaria vaccine, co-developed by the Serum Institute of India (SII) and the University of Oxford, has been launched in Côte d’Ivoire, making it the first country to administer the shot.
The new R21/Matrix-M malaria vaccine utilises Novavax’s Matrix-M adjuvant technology.
Following extensive clinical trials that showcased both its tolerance and safety and found only minor side effects such as injection site pain and fever, R21/Matrix-M was awarded prequalification status by the World Health Organization (WHO) in December 2023.
This certification followed a stringent regulatory review process.
SII has already produced 25 million doses of the vaccine and aims to further increase production to 100 million doses annually.
See Also:MHRA approves Pierre Fabre’s vibegron to treat OAB
Preview
Source: Pharmaceutical Technology
Rusan Pharma’s API Plant in Ankleshwar Receives US FDA GMP Approval
Preview
Source: Pharmaceutical Technology
In line with its mission to provide vaccines affordably and at scale, SII is offering R21/Matrix-M at under $4 per dose.
This production capability is pivotal for rapid and large-scale manufacturing, essential for curbing disease spread and safeguarding those vaccinated.
Côte d’Ivoire has received an initial batch of 656,600 doses and is targeting the immunisation of 250,000 children aged up to 23 months in 16 regions.
Nigeria, Ghana, Burkina Faso and the Central African Republic have also authorised the use of the R21/Matrix-M vaccine.
It stands as the second malaria vaccine available in sub-Saharan Africa after RTS,S.
Oxford University’s Jenner Institute director, Professor Adrian Hill stated: “The roll-out of the R21/Matrix-M malaria vaccine marks the start of a new era in malaria control interventions with the high efficacy vaccine now accessible at a modest price and very large scale to many countries in greatest need.”
Global health organisations such as WHO, Gavi [the Global Alliance for Vaccine and Immunization], UNICEF [the United Nations Childrens Fund] and the Global Fund are collaborating with countries to integrate the vaccine into comprehensive malaria control and prevention strategies.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Targets
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.